Valneva (VALN) Q2 2026 Earnings Call Transcript
Valneva (VALN) reported H1 2026 results: €64M product sales, €63.3M net loss, and €121.5M cash. Sales declined due to reduced distribution and lower IXIARO (€44M) and DUKORAL (€14.7M) revenues. Gross margins fell for both vaccines. The company reaffirmed 2026 guidance: €135M-€150M product sales, €145M-€160M total revenue. Pfizer expects EMA decision on Lyme disease vaccine within 12 months. Valneva is restructuring, consolidating R&D in Vienna, and focusing on cash preservation.
How this was made
The 30-second read
Why it matters
The earnings release provides fresh financial data and guidance, essential for valuation and short‑term trading decisions.
Market read
Valneva's earnings and guidance are the primary catalyst for its stock movement; sector peers may be indirectly affected.
What to watch
Potential upside from upcoming Pfizer regulatory filing and U.S. DoD contract for IXIARO.
Background
Valneva SE is a French biotech focused on vaccines for infectious diseases, listed on NYSE under VALN.
Ticker impact
First report of Valneva's H1 2026 earnings, including net loss of €63.3M, product sales decline and reaffirmed 2026 guidance.
Potential downside pressure in the near term as investors digest weaker results and higher loss.
Earnings are primary disclosure with fresh numbers; market typically reacts to loss widening and guidance reaffirmation.
Market effects
Highlights challenges in travel vaccines and may affect other niche biotech firms with similar pipelines.
European biotech sentiment could be dampened by the weaker French‑listed results.
Limited to biotech sector; no broad macro impact.
Counterpoint
Reaffirmed 2026 revenue guidance could support a bounce if investors focus on cash preservation and upcoming regulatory decisions.
Key entities
- ExecutiveThomas Lingelbach
CEO of Valneva, discussed regulatory timeline for Lyme disease vaccine.
- ExecutivePeter Buhler
CFO, presented financial results and restructuring costs.
